At a glance
What is it—and why does it matter?
Survodutide is an investigational dual agonist of the glucagon receptor and the glucagon-like peptide-1 receptor. The meta-analysis aimed to assess survodutide’s effects on blood sugar control and weight loss in adults. After a single dose (n = 41), AUC0-∞ and Cmax were similar in people with cirrhosis versus healthy individuals (90% CIs for adjusted geometric mean ratios spanned 1).
Sources for this introduction: [1] [2] [3]
This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.
Simple guide
Survodutide, in plain English
The main points from the published research. Each one links to the source it comes from.
What it is
Survodutide is a dual-agonist that targets both the glucagon receptor and the GLP-1 receptor.
Source for this finding
“Survodutide, a novel glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor dual agonist”
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).
What the research looks like
Most published findings come from studies in people.
- 38 People 76%
- 1 Animals or lab 2%
- 11 Other or unclear 22%
Counts show where findings come from, not how strong they are. Animal and lab findings are counted together because study types have not been labelled for this profile yet.
What studies in people found
The two primary end points were percent weight change and achieving at least 5% weight loss by week 76.
Source for this finding
“The two primary end points were the percent change in body weight and a reduction in body weight of at least 5% from baseline to week 76.”
Survodutide Once Weekly for the Treatment of Adults with Obesity.At week 76, at least 5% weight loss occurred in 72.6% (3.6 mg), 71.9% (6.0 mg), and 46.3% (placebo); P < 0.001 vs placebo.
Source for this finding
“72.6%, 71.9% and 46.3% of the participants, respectively, had weight reduction of at least 5% (P < 0.001 for all comparisons with placebo).”
Survodutide Once Weekly for the Treatment of Adults with Obesity.Versus placebo, survodutide lowered HbA1c by a WMD of -0.66%.
Source for this finding
“Compared with placebo, survodutide significantly reduced HbA1c (weighted mean difference [WMD]: -0.66%, 95% confidence interval [CI] [-1.08, -0.23], p = 0.002)”
Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.Primary outcomes included HbA1c, fasting glucagon, body weight, waist circumference, and adverse events.
Source for this finding
“The primary outcomes were changes in glycated haemoglobin (HbA1c), fasting glucagon levels, body weight, waist circumference, along with the incidence of adverse events (AEs).”
Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.In a phase 2 trial in people with obesity without type 2 diabetes, survodutide caused significant weight loss.
Source for this finding
“Survodutide, a novel glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor dual agonist, elicited significant weight loss in a phase 2 trial in individuals with obesity without type 2 diabetes (T2D).”
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).
What animal and lab studies suggest
Not proven in people. Results in animals or cells often do not hold up in humans.
In mice, fluorophore-labeled survodutide was seen to directly access CVOs and nearby hypothalamic and hindbrain nuclei.
Source for this finding
“Using a fluorophore labeled survodutide to visualize sites of action in the mouse brain, survodutide was observed to directly access the CVOs and adjacent hypothalamic and hindbrain nuclei”
Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation.
Safety
No safety findings are published in this profile yet. Missing safety data does not mean it is safe.
What we don't know
- Not yet covered in this profile: administration, contraindications, interactions, regulatory status, safety.
A missing finding does not mean something is safe or effective.
See all 55 findings and sourcesEvery finding, grouped by topic, with its exact source passages
What is it?
A molecule, not a product name.
Identity
Survodutide is a dual-agonist that targets both the glucagon receptor and the GLP-1 receptor.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Survodutide, a novel glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor dual agonist”
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1). · AIMS
Identity
Survodutide is listed as an investigational glucagon receptor agonist (GRA)-based agent.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Several investigational GRA-based agents, including retatrutide, cotadutide, mazdutide, and survodutide, have reported promising results across early and mid-phase clinical trials.”
Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials. · INTRODUCTION
Identity
Survodutide (Ligand ID 13383) is a peptide; its INN is survodutide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Name: survodutide Ligand ID: 13383 Type: Peptide INN: survodutide”
survodutide · Identity and approval
Identity
Survodutide is an investigational dual agonist of the glucagon receptor and the GLP-1 receptor.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Survodutide, an investigational glucagon receptor-GLP-1 receptor dual agonist”
Survodutide Once Weekly for the Treatment of Adults with Obesity. · Abstract
Identity
Survodutide is a dual agonist of the GCG receptor (GCGR) and GLP-1 receptor (GLP-1R).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Survodutide is a novel GCG/GLP-1 receptor (GCGR/GLP-1R) dual agonist”
Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation. · Abstract
Identity
Survodutide is an example of a dual glucagon receptor agonist.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Resmetirom, dual (e.g., cotadutide, survodutide), and triple GRAs (e.g., retarutide) have demonstrated potential efficacy in recent clinical trials.”
Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials. · BACKGROUND
Identity
Sequence component 2 is EGSGSGG.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Component 2: EGSGSGG”
SURVODUTIDE · Sequence
Identity
Survodutide activates both the glucagon receptor and the glucagon-like peptide-1 (GLP-1) receptor.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Survodutide is a glucagon/glucagon-like peptide-1 receptor dual agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).”
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis. · BACKGROUND & AIMS
Identity
Sequence component 1 is HXQGTFTSDYSKYLDERAAKDFIKWLESA.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Component 1: HXQGTFTSDYSKYLDERAAKDFIKWLESA”
SURVODUTIDE · Sequence
Identity
Survodutide is an investigational dual agonist of the glucagon receptor and the glucagon-like peptide-1 receptor.
2 cited sources · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 2 source records.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Survodutide is an investigational glucagon receptor/glucagon-like peptide-1 receptor dual agonist”
Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes. · AIMS
- supports · Source-backed record
“Survodutide is an investigational glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist”
Baseline characteristics in the <scp>SYNCHRONIZE</scp> ™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/ <scp>GLP</scp> ‐1 receptor dual agonist, for obesity in people with type 2 diabetes · Abstract
Identity
Survodutide is an investigational dual agonist of the glucagon receptor and the glucagon-like peptide-1 receptor.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“survodutide, an investigational glucagon and glucagon-like peptide-1 receptor dual agonist”
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2). · OBJECTIVE
Identity
Survodutide is a dual agonist of the glucagon (GCGR) receptor and the GLP-1 receptor.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Clinical studies of GCGR/GLP-1 receptor dual agonists (eg, mazdutide, survodutide)”
Cardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon-Like Peptide-1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus. · Abstract
Identity
Sequence component 3 is DIQMTQSPSSLSASVGDRVTINCQASQSIYNNNELSWYQQKPGKPPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCGGYKSYSNDGNGFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Component 3: DIQMTQSPSSLSASVGDRVTINCQASQSIYNNNELSWYQQKPGKPPKLLIYRASTLASGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCGGYKSYSNDGNGFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC”
SURVODUTIDE · Sequence
Identity
This review included trials of survodutide (along with tirzepatide, pemvidutide, retatrutide, and cotadutide).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The included GLP-1-based polyagonists-tirzepatide, survodutide, pemvidutide, retatrutide, and cotadutide-”
Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis. · Abstract
Identity
Survodutide (BI 456906) is a long-acting dual agonist of the glucagon receptor and the GLP-1 receptor.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Survodutide (BI 456906) is a long-acting glucagon/GLP-1 receptor dual agonist [Reference 47623].”
IUPHAR ligand commentary · General comments
Identity
Survodutide is listed as a newer GLP-1 receptor agonist-based agent for obesity.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“This Review synthesises evidence from randomised controlled trials and high-quality meta-analyses on approved and late-stage investigational obesity medications, including phentermine-topiramate, naltrexone-bupropion, glucagon-like peptide-1 (GLP-1) receptor agonists (eg, liraglutide, semaglutide, subcutaneously and orally), and newer GLP-1 receptor agonist-based agents (eg, tirzepatide, survodutide, mazdutide, retatrutide, cagrilintide-semaglutide, and amycretin).”
Beyond weight loss: multisystem benefits of obesity medications. · Abstract
Identity
Survodutide is described as a glucagon-containing anti-obesity medication.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Newer multi-receptor agents act with greater metabolic specificity: glucagon-containing agents such as survodutide and the triple agonist retatrutide”
Anti-Obesity Medications in Longevity and Aesthetic Medicine. · Abstract
Identity
Survodutide is a protein.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Molecule type: Protein”
SURVODUTIDE · Molecule identity
How does it work?
Target, response, and disposition.
Mechanism
The primary end points were percent change in body weight and achieving at least 5% weight loss from baseline to week 76.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The two primary end points were the percent change in body weight and a reduction in body weight of at least 5% from baseline to week 76.”
Survodutide Once Weekly for the Treatment of Adults with Obesity. · Abstract
Mechanism
In mice, fluorophore-labeled survodutide was seen to directly access CVOs and nearby hypothalamic and hindbrain nuclei.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Using a fluorophore labeled survodutide to visualize sites of action in the mouse brain, survodutide was observed to directly access the CVOs and adjacent hypothalamic and hindbrain nuclei”
Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation. · Abstract
Pharmacokinetics
The single-dose part of the study mainly measured AUC0-∞ and Cmax.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“the primary endpoints were the area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) and maximal plasma concentration (Cmax).”
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis. · METHODS
Pharmacokinetics
After a single dose (n = 41), AUC0-∞ and Cmax were similar in people with cirrhosis versus healthy individuals (90% CIs for adjusted geometric mean ratios spanned 1).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“In the single-dose cohorts (n = 41), mean AUC0-∞and Cmaxwere similar in those with cirrhosis compared with healthy individuals (90% CIs for adjusted geometric mean ratios spanned 1).”
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis. · RESULTS
What has been studied?
What the evidence says.
Study findings
The two primary end points were percent weight change and achieving at least 5% weight loss by week 76.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The two primary end points were the percent change in body weight and a reduction in body weight of at least 5% from baseline to week 76.”
Survodutide Once Weekly for the Treatment of Adults with Obesity. · METHODS
Study findings
At week 76, at least 5% weight loss occurred in 72.6% (3.6 mg), 71.9% (6.0 mg), and 46.3% (placebo); P < 0.001 vs placebo.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“72.6%, 71.9% and 46.3% of the participants, respectively, had weight reduction of at least 5% (P < 0.001 for all comparisons with placebo).”
Survodutide Once Weekly for the Treatment of Adults with Obesity. · Abstract
Study findings
Versus placebo, survodutide lowered HbA1c by a WMD of -0.66%.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Compared with placebo, survodutide significantly reduced HbA1c (weighted mean difference [WMD]: -0.66%, 95% confidence interval [CI] [-1.08, -0.23], p = 0.002)”
Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis. · RESULTS
Study findings
Primary outcomes included HbA1c, fasting glucagon, body weight, waist circumference, and adverse events.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The primary outcomes were changes in glycated haemoglobin (HbA1c), fasting glucagon levels, body weight, waist circumference, along with the incidence of adverse events (AEs).”
Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis. · METHODS
Study findings
In a phase 2 trial in people with obesity without type 2 diabetes, survodutide caused significant weight loss.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Survodutide, a novel glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor dual agonist, elicited significant weight loss in a phase 2 trial in individuals with obesity without type 2 diabetes (T2D).”
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1). · AIMS
Study findings
In a network meta-analysis of five RCTs in biopsy-confirmed MASH without cirrhosis, survodutide (2.4 mg/wk or 4.8-6 mg/wk) improved fibrosis versus placebo (I2= 0% for active treatments).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Data from five RCTs (N = 1667) were included. All active treatments, including Dapagliflozin 10 mg, Survodutide (2.4 mg/wk, 4.8-6 mg/wk), Tirzepatide (5 mg/wk, 10-15 mg/wk), and Semaglutide (0.7-1.4 mg/wk, 2.4 or 2.8 mg/wk), improved fibrosis versus placebo (I2= 0%).”
Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: A network meta-analysis. · RESULTS
Study findings
By week 76, mean weight change was -12.2% with 3.6 mg, -13.0% with 6.0 mg, and -5.4% with placebo (treatment-regimen estimand).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“At week 76, the mean change in body weight from baseline according to the treatment-regimen estimand was -12.2% (95% confidence interval [CI], -13.6 to -10.8) in the 3.6-mg group, -13.0% (95% CI, -14.4 to -11.6) in the 6.0-mg group, and -5.4% (95% CI, -6.9 to -4.0) in the placebo group”
Survodutide Once Weekly for the Treatment of Adults with Obesity. · Abstract
Study findings
In trial 1404-0036, there was no significant change in HOMA-β with survodutide versus placebo.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“In trial 1404-0036, there was no significant change in HOMA-β with survodutide versus placebo”
Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity. · RESULTS
Study findings
Versus placebo, survodutide lowered fasting glucagon by a WMD of -7 pmol/L.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“and fasting glucagon levels (WMD: -7 pmol/L, 95% CI [-10.3, -3.69], p = 0.016).”
Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis. · RESULTS
Study findings
By the efficacy estimand, 84.2% on survodutide vs 24.3% on placebo had at least a 30% reduction in MRI-PDFF liver fat (P < 0.0001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“treatment regimen estimand: 68.5% versus 28.6%, respectively; P < 0.0001).”
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. · Abstract
- supports · Source-backed record
“In total, 84.2% of survodutide-treated patients versus 24.3% of placebo-treated patients had ≥30% reduction in LFC using the efficacy estimand (P < 0.0001;”
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. · Abstract
Study findings
In trial 1404-0036, survodutide significantly decreased HOMA-IR, glucagon, C-peptide, fasting insulin, and fasting plasma glucose versus placebo, and significantly increased high-molecular-weight adiponectin.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Survodutide was associated with significant decreases in HOMA-IR, glucagon, C-peptide, fasting insulin, and FPG versus placebo, and significant increases in HMW adiponectin.”
Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity. · RESULTS
Study findings
Primary end points were percent weight change and losing at least 5% of body weight by week 76.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The two primary end points were the percent change in body weight and a reduction in body weight of at least 5% from baseline to week 76.”
Survodutide Once Weekly for the Treatment of Adults with Obesity. · METHODS
Study findings
A post hoc analysis evaluated survodutide effects on beta-cell function, insulin sensitivity, and glucose biomarkers in two phase 2 trial populations.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“This post hoc analysis evaluated the effect of survodutide on beta-cell function, insulin sensitivity, and glucose biomarkers in two phase 2 trial populations.”
Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity. · AIMS
Study findings
The meta-analysis included six RCTs with 1272 participants.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Six RCTs involving 1272 participants were included in this meta-analysis.”
Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis. · RESULTS
Study findings
How long beta-cell improvements last after stopping treatment is unknown.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The durability of beta-cell improvements after treatment cessation remains unknown.”
Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity. · CONCLUSIONS
Study findings
Survodutide reduced body weight significantly more than placebo in adults with obesity without diabetes.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Survodutide led to significantly greater reductions in body weight than placebo in adults with obesity without diabetes.”
Survodutide Once Weekly for the Treatment of Adults with Obesity. · Abstract
Study findings
Versus placebo, survodutide reduced body weight by a WMD of -6.7 kg.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Survodutide also significantly decreased body weight (WMD: -6.7 kg, 95% CI [-10.0, -3.4], p < 0.001)”
Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis. · RESULTS
Study findings
Across survodutide dose groups, bodyweight change from baseline explained the largest proportion of variability in changes in fasting insulin and HOMA-IR.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Combining all survodutide dose groups for each trial, absolute change in bodyweight from baseline explained the largest proportion of total variability in changes from baseline in fasting insulin and HOMA-IR.”
Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity. · RESULTS
Study findings
At week 76, at least 5% weight loss occurred in 72.6% (3.6 mg), 71.9% (6.0 mg), and 46.3% (placebo); P<0.001 vs placebo.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“72.6%, 71.9% and 46.3% of the participants, respectively, had weight reduction of at least 5% (P<0.001 for all comparisons with placebo).”
Survodutide Once Weekly for the Treatment of Adults with Obesity. · RESULTS
Study findings
In trial 1404-0002, survodutide was associated with significant decreases in HOMA-IR, glucagon, and fasting plasma glucose versus placebo.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“with significant decreases in HOMA-IR, glucagon, and fasting plasma glucose (FPG).”
Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity. · RESULTS
Study findings
The meta-analysis aimed to assess survodutide’s effects on blood sugar control and weight loss in adults.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“This meta-analysis aimed to evaluate the efficacy and safety of survodutide on glycemic control and weight loss in adults.”
Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis. · AIM
Study findings
Bigger decreases in body weight and waist circumference were seen with >2.4 mg weekly and treatment >16 weeks.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“with enhanced effects observed at higher total weekly doses (>2.4 mg) and longer treatment durations (>16 weeks).”
Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis. · RESULTS
Study findings
In a phase 3 trial, once-weekly survodutide 6.0 mg met the co-primary endpoints for reducing liver fat (by MRI-PDFF) and changing body weight at week 48.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The co-primary endpoints, ≥30% reduction in magnetic resonance imaging-proton density fat fraction (MRI-PDFF)-assessed liver fat content (LFC) and percentage change in body weight (both baseline to week 48), were met.”
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. · Abstract
Study findings
In trial 1404-0002, survodutide was associated with significant and rapid increases in HOMA-β versus placebo.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“In trial 1404-0002, survodutide was associated with significant and rapid increases in HOMA-β versus placebo”
Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity. · RESULTS
Study findings
By the treatment regimen estimand, mean body weight change was -8.7% with survodutide vs -1.4% with placebo (P < 0.0001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“treatment regimen estimand: -8.7% versus -1.4%, respectively; P < 0.0001).”
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. · Abstract
- supports · Source-backed record
“Mean percentage change in body weight was -12.2% with survodutide and -1.0% with placebo using the efficacy estimand (P < 0.0001;”
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. · Abstract
Study findings
Across the analysed trials, survodutide reduced weight versus placebo by a mean difference of -10.74 kg (95% CI [-15.68, -5.80]).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Retatrutide demonstrated the greatest weight reduction versus placebo (MD -13.44 kg; 95% CI [-18.38, -8.51]), followed by survodutide (MD -10.74 kg; 95% CI [-15.68, -5.80]) and mazdutide (MD -6.47 kg; 95% CI [-10.71, -2.24]).”
Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials. · RESULTS
Study findings
By week 76, average weight change was -12.2% (3.6 mg), -13.0% (6.0 mg), and -5.4% (placebo).
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“At week 76, the mean change in body weight from baseline according to the treatment-regimen estimand was -12.2% (95% confidence interval [CI], -13.6 to -10.8) in the 3.6-mg group, -13.0% (95% CI, -14.4 to -11.6) in the 6.0-mg group, and -5.4% (95% CI, -6.9 to -4.0) in the placebo group”
Survodutide Once Weekly for the Treatment of Adults with Obesity. · RESULTS
Study findings
Versus placebo, survodutide reduced waist circumference by a WMD of -7.09 cm.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“and waist circumference (WMD: -7.09 cm, 95% CI [-9.44, -4.47], p < 0.001),”
Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis. · RESULTS
Risks and interactions
Risks, organized for scanning.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Products and regulatory status
Same ingredient. Different records.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Administration context
The practical clinical context.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Additional research & classification gaps
5 archived statements are kept separate from drug-effect findings. Media studies, economic models, methods, and records with unresolved scope are not used as medical-effect evidence.
Inspect contextual research (5)
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The analysis calculated total, direct, and indirect effects comparing survodutide with placebo.
Research context only—not evidence of a treatment effect.
- Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.
Total, direct (weight reduction-independent), and indirect (weight reduction-dependent) treatment effects were calculated for survodutide versus placebo.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Survodutide’s ChEMBL ID is CHEMBL5314776.
Research context only—not evidence of a treatment effect.
- SURVODUTIDE
ChEMBL ID: CHEMBL5314776
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The preferred name is SURVODUTIDE.
Research context only—not evidence of a treatment effect.
- SURVODUTIDE
Preferred name: SURVODUTIDE
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The model treated treatment as the exposure and percent weight change as the mediator, adjusting for baseline weight, type 2 diabetes, and fibrosis stage.
Research context only—not evidence of a treatment effect.
- Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.
The causal mediation analysis model included treatment (exposure) and percentage change in body weight (mediator), with baseline body weight, type 2 diabetes status, and fibrosis stage as covariates.
1 cited source · 1 linked study ID
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record.
The analysis estimated how much of survodutide’s effect was direct versus mediated by weight loss.
Research context only—not evidence of a treatment effect.
- Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.
This post hoc mediation analysis evaluated the proportion of the direct treatment effect versus the indirect effect mediated by weight reduction.
Research status + gaps
What still needs better answers?
- Not yet covered in this profile: administration, contraindications, interactions, regulatory status, safety.
- Some extracted findings are not shown because they did not pass Peplexicon's automated evidence checks.
These are the limits of this profile, not an exhaustive list of scientific uncertainties.
References + discovery
Open the records yourself.
- SURVODUTIDE ↗
chembl-molecule · published August 29, 2026 · retrieved August 29, 2026
- Survodutide Once Weekly for the Treatment of Adults with Obesity. ↗
doi · published June 7, 2026 · retrieved September 4, 2026
- Baseline characteristics in the <scp>SYNCHRONIZE</scp> ™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/ <scp>GLP</scp> ‐1 receptor dual agonist, for obesity in people with type 2 diabetes ↗
doi · published November 11, 2025 · retrieved September 4, 2026
- IUPHAR ligand commentary ↗
iuphar-comments · published August 29, 2026 · retrieved August 29, 2026
- survodutide ↗
iuphar-ligand · published August 29, 2026 · retrieved August 29, 2026
- Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis. ↗
pubmed · published November 1, 2024 · retrieved September 9, 2026
- Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2). ↗
pubmed · published January 1, 2025 · retrieved September 9, 2026
- Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis. ↗
pubmed · published December 1, 2025 · retrieved September 7, 2026
- Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: A network meta-analysis. ↗
pubmed · published January 1, 2026 · retrieved September 7, 2026
- Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1). ↗
pubmed · published January 1, 2026 · retrieved September 7, 2026
- Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes. ↗
pubmed · published February 1, 2026 · retrieved September 7, 2026
- Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta-Analysis of Clinical Trials. ↗
pubmed · published January 1, 2026 · retrieved September 7, 2026
- Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation. ↗
pubmed · published March 1, 2026 · retrieved September 7, 2026
- Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials. ↗
pubmed · published March 1, 2026 · retrieved September 6, 2026
- Beyond weight loss: multisystem benefits of obesity medications. ↗
pubmed · published August 1, 2026 · retrieved August 21, 2026
- Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. ↗
pubmed · published August 1, 2026 · retrieved September 7, 2026
- Survodutide Once Weekly for the Treatment of Adults with Obesity. ↗
pubmed · published August 20, 2026 · retrieved August 29, 2026
- Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity. ↗
pubmed · published September 1, 2026 · retrieved September 2, 2026
- Efficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis. ↗
pubmed · published June 1, 2026 · retrieved August 29, 2026
- Cardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon-Like Peptide-1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus. ↗
pubmed · published August 4, 2026 · retrieved August 28, 2026
- Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH. ↗
pubmed · published August 3, 2026 · retrieved September 7, 2026
- Anti-Obesity Medications in Longevity and Aesthetic Medicine. ↗
pubmed · published August 3, 2026 · retrieved August 18, 2026
Publication history and provenance
Version 10 · Automated assessment · September 9, 2026
a7e68832d235eb3c34ae43d942dcf0a7892faa389db117d0d1b53b8f129aeb45